{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:58:57Z","timestamp":1771844337065,"version":"3.50.1"},"reference-count":74,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Parkinson disease (PD) and mood disorders represent two substantial global health burdens that increasingly co-occur as both conditions rise in prevalence worldwide. Diagnosing Parkinson disease in patients with pre-existing mood disorders is clinically challenging due to overlapping symptoms, medication effects, and shared neurobiological mechanisms. Apathy, psychomotor slowing, and fatigue may mimic depressive symptoms, leading to delayed recognition of early parkinsonism. Development of an underlying neurodegenerative disorder could account for some treatment-resistant symptoms or treatment failures if not recognized. Therefore, the identification of PD will change the treatment and management plan significantly. Accurate diagnosis of PD requires a detailed neurologic examination focusing on bradykinesia, rigidity, and resting tremor, supported when appropriate by dopamine transporter imaging (DaT scan) or other emerging biomarkers. Understanding the temporal relationship between psychiatric and motor features helps differentiate prodromal PD from primary mood disorders. Management of patients with both mood disorders and PD integrates dopaminergic replacement therapy for motor symptoms with individualized treatment of psychiatric comorbidities. Levodopa remains the cornerstone for motor control, while dopamine agonists, MAO-B inhibitors, and COMT inhibitors can be added as needed. For depression and anxiety, SSRIs and SNRIs are first-line choices; quetiapine or clozapine are preferred when treatment for psychosis is necessary. Intentional, thoughtful polypharmacy is frequently required. Non-pharmacologic interventions\u2014including cognitive behavioral therapy, structured exercise, and patient\u2013caregiver education\u2014enhance mood, function, and quality of life. Multidisciplinary collaboration between neurology, psychiatry, and allied health professionals is essential for optimal outcomes. This review offers guidance to healthcare providers as well as other interested parties involved in patients with mood disorders who may also be developing or have PD, especially to those who may have limited access to neurologic resources.<\/jats:p>","DOI":"10.3390\/ijerph23020269","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:00:52Z","timestamp":1771840852000},"page":"269","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnosis and Management of Parkinson Disease in Individuals with Pre-Existing Mood Disorders"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6149","authenticated-orcid":false,"given":"Laura","family":"Buyan Dent","sequence":"first","affiliation":[{"name":"School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705-2281, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/ije\/dyu038","article-title":"The global prevalence of common mental disorders: A systematic review and meta-analysis 1980\u20132013","volume":"43","author":"Steel","year":"2014","journal-title":"Int. J. Epidemiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_3","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators (2018). Global, regional, and national burden of Parkinson\u2019s Disease, 1990\u20132016: A systematic analysis for the global Burden of Disease Study 2016. Lancet Neurol., 17, 939\u2013953."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/08919887211018267","article-title":"Mood Disorders and Anxiety in Parkinson\u2019s Disease: Current Concepts","volume":"34","author":"Lintel","year":"2021","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00702-019-02019-7","article-title":"Neuropsychiatric aspects of Parkinson\u2019s disease","volume":"126","author":"Nagy","year":"2019","journal-title":"J. Neural Transm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/jamaneurol.2022.3902","article-title":"Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease","volume":"80","author":"Schrag","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/mds.24996","article-title":"Identifying prodromal Parkinson\u2019s disease: Pre-motor disorders in Parkinson\u2019s disease","volume":"27","author":"Postuma","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_8","unstructured":"Parkinson, J. (1817). An Essay on the Shaking Palsy, Sherwood, Neely, and Jones."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.irn.2017.01.003","article-title":"Hallmarks of Clinical Aspects of Parkinson\u2019s Disease Through Centuries","volume":"132","author":"Bhattacharyya","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"a008862","DOI":"10.1101\/cshperspect.a008862","article-title":"The history of Parkinson\u2019s disease: Early clinical descriptions and neurological therapies","volume":"1","author":"Goetz","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mds.26102","article-title":"The medical treatment of Parkinson disease from James Parkinson to George Cotzias","volume":"30","author":"Fahn","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(73)92729-3","article-title":"A year\u2019s comparison of treatment of patients with Parkinson\u2019s disease with levodopa combined with carbidopa versus treatment with levodopa alone","volume":"302","author":"Marsden","year":"1973","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104749","DOI":"10.1016\/j.neubiorev.2022.104749","article-title":"Prevalence and clinical aspects of depression in Parkinson\u2019s disease: A systematic review and meta-analysis of 129 studies","volume":"141","author":"Cong","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/NMD.0000000000001537","article-title":"Morbidity and Associated Factors of Depressive Disorder in Patients With Parkinson\u2019s Disease","volume":"210","author":"Lee","year":"2022","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11920-021-01229-9","article-title":"The Relationship Between Anxiety Disorders and Parkinson\u2019s Disease: Clinical and Therapeutic Issues","volume":"23","author":"Naja","year":"2021","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1017\/S1092852920002126","article-title":"Bipolar Spectrum disorders in Parkinson\u2019s disease: A systematic evaluation","volume":"27","author":"Bacciardi","year":"2022","journal-title":"CNS Spectr."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Szatm\u00e1ri, S., Ajtay, A., Oberfrank, F., Dobi, B., and Bereczki, D. (2020). The prevalence of psychiatric symptoms before the diagnosis of Parkinson\u2019s disease in a nationwide cohort: A comparison to patients with cerebral infarction. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0236728"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107717","DOI":"10.1016\/j.phrs.2025.107717","article-title":"Multidimensional mechanisms of anxiety and depression in Parkinson\u2019s disease: Integrating neuroimaging, neurocircuits, and molecular pathways","volume":"215","author":"Zhao","year":"2025","journal-title":"Pharmacol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/jamaneurol.2017.4243","article-title":"When Do \u03b1-Synucleinopathies Start? An Epidemiological Timeline: A Review","volume":"75","author":"Savica","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_20","first-page":"966","article-title":"Neuroanatomical and prognostic associations of depression in Parkinson\u2019s disease","volume":"95","author":"Badenoch","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1212\/CPJ.0000000000001016","article-title":"Clinical Diagnostic Accuracy of early\/advanced Parkinson Disease","volume":"11","author":"Adler","year":"2021","journal-title":"Neurol. Clin. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMra2401857","article-title":"Parkinson\u2019s Disease","volume":"391","author":"Tanner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaneurol.2025.0112","article-title":"Automated Imaging Differentiation for Parkinsonism","volume":"82","author":"Vaillancourt","year":"2025","journal-title":"JAMA Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41531-021-00185-8","article-title":"Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: A systematic review and meta-analysis","volume":"7","author":"Bega","year":"2021","journal-title":"npj Park. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00702-021-02452-7","article-title":"Dopamine transporter (DAT) imaging in Parkinson\u2019s disease and related disorders","volume":"129","year":"2022","journal-title":"J. Neural Transm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1529","DOI":"10.1212\/WNL.0000000000206772","article-title":"Cutaneous \u03b1-Synuclein Signatures in Patients with Multiple System Atrophy and Parkinson Disease","volume":"100","author":"Gibbons","year":"2023","journal-title":"Neurology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1001\/jamaneurol.2019.3446","article-title":"Risk of Developing Parkinson Disease in Bipolar Disorder: A Systematic Review and Meta-analysis","volume":"77","author":"Faustino","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","article-title":"Progress towards therapies for disease modification in Parkinson\u2019s disease","volume":"20","author":"Vijiaratnam","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson\u2019s disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40266-022-00942-1","article-title":"Depression in Patients with Parkinson\u2019s Disease: Current Understanding of its Neurobiology and Implications for Treatment","volume":"39","author":"Prange","year":"2022","journal-title":"Drugs Aging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101840","DOI":"10.1016\/j.arr.2022.101840","article-title":"Neurobiology of depression in Parkinson\u2019s disease: Insights into epidemiology, molecular mechanisms and treatment strategies","volume":"85","author":"Ahmad","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"106115","DOI":"10.1016\/j.nbd.2023.106115","article-title":"Mood disturbances in Parkinson\u2019s disease: From prodromal origins to application of animal models","volume":"181","author":"Hayley","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102392","DOI":"10.1016\/j.jchemneu.2024.102392","article-title":"The habenula in Parkinson\u2019s disease: Anatomy, function, and implications for mood disorders\u2014A narrative review","volume":"136","author":"Samanci","year":"2024","journal-title":"J. Chem. Neuroanat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbr.2018.03.011","article-title":"Abnormal ventral tegmental area-anterior cingulate cortex connectivity in Parkinson\u2019s disease with depression","volume":"347","author":"Wei","year":"2018","journal-title":"Behav. Brain Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2016.11.009","article-title":"Changes in neural circuitry associated with depression at pre-clinical, pre-motor and early motor phases of Parkinson\u2019s disease","volume":"35","author":"Borgonovo","year":"2017","journal-title":"Park. Relat. Disord."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e068718","DOI":"10.1136\/bmj-2021-068718","article-title":"Management of psychiatric and cognitive complications in Parkinson\u2019s disease","volume":"379","author":"Weintraub","year":"2022","journal-title":"BMJ"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"121631","DOI":"10.1016\/j.neuroimage.2025.121631","article-title":"Individualized functional connectivity markers for motor and mood symptoms of Parkinson\u2019s disease","volume":"324","author":"Dahmani","year":"2025","journal-title":"Neuroimage"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wang, E., Jia, Y., Cheng, L., Mao, C., Bao, Y., Shen, J., Zhang, Y., and Fan, G. (2025). Convergent reductions in interhemispheric functional, structural and callosal connectivity in Parkinson\u2019s disease. Front. Aging Neurosci., 17.","DOI":"10.3389\/fnagi.2025.1512130"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e26776","DOI":"10.1002\/hbm.26776","article-title":"Dynamic properties in functional connectivity changes and striatal dopamine deficiency in Parkinson\u2019s disease","volume":"45","author":"Asendorf","year":"2024","journal-title":"Hum. Brain Mapp."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1474-4422(15)00019-8","article-title":"Apathy in Parkinson\u2019s disease: Clinical features, neural substrates, diagnosis, and treatment","volume":"14","author":"Pagonabarraga","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/jnnp-2022-330790","article-title":"Longitudinal decline in striatal dopamine transporter binding in Parkinson\u2019s disease: Associations with apathy and anhedonia","volume":"94","author":"Costello","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Angelopoulou, E., Stanitsa, E., Karpodini, C.C., Bougea, A., Kontaxopoulou, D., Fragkiadaki, S., Koros, C., Georgakopoulou, V.E., Fotakopoulos, G., and Koutedakis, Y. (2023). Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson\u2019s Disease: An Updated Review. Medicina, 59.","DOI":"10.3390\/medicina59081454"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaneurol.2019.0534","article-title":"Effects of Mindfulness Yoga vs Stretching and Resistance Training Exercises on Anxiety and Depression for People with Parkinson Disease: A Randomized Clinical Trial","volume":"76","author":"Kwok","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamaneurol.2022.1783","article-title":"Six Action Steps to Address Global Disparities in Parkinson Disease: A World Health Organization Priority","volume":"79","author":"Schiess","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1007\/s10072-024-07659-6","article-title":"Efficacy of cognitive behavioral therapy for anxiety and depression in Parkinson\u2019s disease patients: An updated systematic review and meta-analysis","volume":"45","author":"Alnajjar","year":"2024","journal-title":"Neurol. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Wu, X., Shi, M., Lian, Y., and Zhang, H. (2024). Cognitive behavioral therapy approaches to the improvement of mental health in Parkinson\u2019s disease patients: A systematic review and meta-analysis. BMC Neurol., 24.","DOI":"10.1186\/s12883-024-03859-x"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"105456","DOI":"10.1016\/j.parkreldis.2023.105456","article-title":"Reducing depression and anxiety symptoms in patients with Parkinson\u2019s disease: The effectiveness of group cognitive behavioral therapy","volume":"112","author":"Gashtil","year":"2023","journal-title":"Park. Relat. Disord."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/08919887211018274","article-title":"The Growing Role of Cognitive Behavior Therapy in the Treatment of Parkinson\u2019s Disease","volume":"34","author":"Lopes","year":"2021","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jamda.2021.03.031","article-title":"Psychotherapy for the Treatment of Anxiety and Depression in Patients with Parkinson Disease: A Meta-Analysis of Randomized Controlled Trials","volume":"22","author":"Hong","year":"2021","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2174\/1570159X14666151208114634","article-title":"Revisiting the Medical Management of Parkinson\u2019s Disease: Levodopa versus Dopamine Agonist","volume":"14","author":"Zhang","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","article-title":"Medical, surgical, and physical treatments for Parkinson\u2019s disease","volume":"403","author":"Foltynie","year":"2024","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Nakmode, D.D., Day, C.M., Song, Y., and Garg, S. (2023). The Management of Parkinson\u2019s Disease: An Overview of the Current Advancements in Drug Delivery Systems. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15051503"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S1474-4422(25)00210-8","article-title":"Focused ultrasound therapy for movement disorders","volume":"24","author":"Paschen","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"111050","DOI":"10.1016\/j.jocn.2025.111050","article-title":"Gamma knife versus linear accelerator thalamotomy for essential tremor and Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"133","author":"Chintapalli","year":"2025","journal-title":"J. Clin. Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"175070","DOI":"10.1016\/j.ejphar.2022.175070","article-title":"Comparative efficacy and acceptability of drug treatments for Parkinson\u2019s disease with depression: A systematic review with network meta-analysis","volume":"927","author":"Wang","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/gps.4834","article-title":"Efficacy and tolerability of antidepressants in Parkinson\u2019s disease: A systematic review and network meta-analysis","volume":"33","author":"Mills","year":"2018","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Liu, J., Dong, J., Wang, L., Su, Y., Yan, P., and Sun, S. (2013). Comparative efficacy and acceptability of antidepressants in Parkinson\u2019s disease: A network meta-analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076651"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jagp.2021.02.037","article-title":"Optimal Treatment of Depression and Anxiety in Parkinson\u2019s Disease","volume":"29","author":"Pontone","year":"2021","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/14737175.2019.1636648","article-title":"Treatment of psychiatric disturbances in hypokinetic movement disorders","volume":"19","author":"Berardelli","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/14656566.2023.2240228","article-title":"The pharmacological management of the behavioral aspects of Parkinson\u2019s disease: An update","volume":"24","author":"Campagnolo","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.48.4.1070","article-title":"Parkinson Study Group. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson\u2019s disease","volume":"48","author":"Richard","year":"1997","journal-title":"Neurology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/phar.1500","article-title":"STACCATO Study Investigators. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: Retrospective study (STACCATO)","volume":"34","author":"Panisset","year":"2014","journal-title":"Pharmacotherapy"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40263-018-0540-6","article-title":"Assessment and Management of Neuropsychiatric Symptoms in Parkinson\u2019s Disease","volume":"32","author":"Mueller","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2020.10.020","article-title":"A trial of buspirone for anxiety in Parkinson\u2019s disease: Safety and tolerability","volume":"81","author":"Schneider","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40263-016-0341-8","article-title":"Valproate-Associated Parkinsonism: A Critical Review of the Literature","volume":"30","author":"Brugger","year":"2016","journal-title":"CNS Drugs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1212\/WNL.47.3.626","article-title":"Reversible parkinsonism and cognitive impairment with chronic valproate use","volume":"47","author":"Armon","year":"1996","journal-title":"Neurology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.parkreldis.2013.03.016","article-title":"Valproic acid-induced parkinsonism: Levodopa responsiveness with dyskinesia","volume":"19","author":"Silver","year":"2013","journal-title":"Park. Relat. Disord."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1474-4422(19)30152-8","article-title":"Recent developments in drug-induced movement disorders: A mixed picture","volume":"18","author":"Factor","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/mds.25194","article-title":"Effectiveness of multidisciplinary care for Parkinson\u2019s disease: A randomized, controlled trial","volume":"28","author":"Bloem","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/mds.28097","article-title":"Integrated Care in Parkinson\u2019s Disease: A Systematic Review and Meta-Analysis","volume":"35","author":"Rajan","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/0891988720915525","article-title":"Exploring Nonmotor Neuropsychiatric Manifestations of Parkinson Disease in a Comprehensive Care Setting","volume":"34","author":"Dhingra","year":"2021","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/mds.28332","article-title":"Pilot Evaluation of a Pragmatic Network for Integrated Care and Self-Management in Parkinson\u2019s Disease","volume":"36","author":"Mestre","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"107931","DOI":"10.1016\/j.pec.2023.107931","article-title":"A Parkinson care-coordinator may make a difference: A scoping review on multi-sectoral integrated care initiatives for people living with Parkinson\u2019s disease and their caregivers","volume":"116","author":"Vester","year":"2023","journal-title":"Patient Educ. Couns."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/23\/2\/269\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:02:20Z","timestamp":1771840940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/23\/2\/269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":74,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijerph23020269"],"URL":"https:\/\/doi.org\/10.3390\/ijerph23020269","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]}}}